395 related articles for article (PubMed ID: 10207169)
21. Large neutral amino acids in the treatment of phenylketonuria (PKU).
Matalon R; Michals-Matalon K; Bhatia G; Grechanina E; Novikov P; McDonald JD; Grady J; Tyring SK; Guttler F
J Inherit Metab Dis; 2006 Dec; 29(6):732-8. PubMed ID: 16988900
[TBL] [Abstract][Full Text] [Related]
22. Large Neutral Amino Acid Therapy Increases Tyrosine Levels in Adult Patients with Phenylketonuria: A Long-Term Study.
Burlina AP; Cazzorla C; Massa P; Polo G; Loro C; Gueraldi D; Burlina AB
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31640267
[TBL] [Abstract][Full Text] [Related]
23. Brain imaging and proton magnetic resonance spectroscopy in patients with phenylketonuria.
Möller HE; Weglage J; Bick U; Wiedermann D; Feldmann R; Ullrich K
Pediatrics; 2003 Dec; 112(6 Pt 2):1580-3. PubMed ID: 14654669
[TBL] [Abstract][Full Text] [Related]
24. Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria.
Möller HE; Weglage J; Wiedermann D; Ullrich K
J Cereb Blood Flow Metab; 1998 Nov; 18(11):1184-91. PubMed ID: 9809507
[TBL] [Abstract][Full Text] [Related]
25. Multicompartment analysis of protein-restricted phenylketonuric mice reveals amino acid imbalances in brain.
Vogel KR; Arning E; Bottiglieri T; Gibson KM
J Inherit Metab Dis; 2017 Mar; 40(2):227-235. PubMed ID: 27761676
[TBL] [Abstract][Full Text] [Related]
26. The Benefit of Large Neutral Amino Acid Supplementation to a Liberalized Phenylalanine-Restricted Diet in Adult Phenylketonuria Patients: Evidence from Adult
van Vliet D; van der Goot E; van Ginkel WG; van Faassen MHJR; de Blaauw P; Kema IP; Martinez A; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
Nutrients; 2019 Sep; 11(9):. PubMed ID: 31546852
[TBL] [Abstract][Full Text] [Related]
27. Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria.
Knudsen GM; Hasselbalch S; Toft PB; Christensen E; Paulson OB; Lou H
J Inherit Metab Dis; 1995; 18(6):653-64. PubMed ID: 8750601
[TBL] [Abstract][Full Text] [Related]
28. The dynamics of brain concentrations of phenylalanine and its clinical significance in patients with phenylketonuria determined by in vivo 1H magnetic resonance spectroscopy.
Pietz J; Kreis R; Boesch C; Penzien J; Rating D; Herschkowitz N
Pediatr Res; 1995 Nov; 38(5):657-63. PubMed ID: 8552430
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting neutral amino acid transport for the treatment of phenylketonuria.
Belanger AM; Przybylska M; Gefteas E; Furgerson M; Geller S; Kloss A; Cheng SH; Zhu Y; Yew NS
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046012
[TBL] [Abstract][Full Text] [Related]
30. The increasing importance of LNAA supplementation in phenylketonuria at higher plasma phenylalanine concentrations.
van Vliet D; van der Goot E; van Ginkel WG; van Faassen HJR; de Blaauw P; Kema IP; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
Mol Genet Metab; 2022 Jan; 135(1):27-34. PubMed ID: 34974973
[TBL] [Abstract][Full Text] [Related]
31. The Impact of a Slow-Release Large Neutral Amino Acids Supplement on Treatment Adherence in Adult Patients with Phenylketonuria.
Burlina AP; Cazzorla C; Massa P; Loro C; Gueraldi D; Burlina AB
Nutrients; 2020 Jul; 12(7):. PubMed ID: 32674279
[TBL] [Abstract][Full Text] [Related]
32. Propagation of Plasma L-Phenylalanine Concentration Fluctuations to the Neurovascular Unit in Phenylketonuria: An
Taslimifar M; Buoso S; Verrey F; Kurtcuoglu V
Front Physiol; 2019; 10():360. PubMed ID: 31105574
[TBL] [Abstract][Full Text] [Related]
33. Improvement, cloning, and expression of an in silico designed protein enriched with large neutral amino acids in Pichia pastoris for possible application in phenylketonuria.
Appaiah P; Vasu P
J Food Biochem; 2020 Mar; 44(3):e13151. PubMed ID: 31960483
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria.
Leuzzi V; Bianchi MC; Tosetti M; Carducci CL; Carducci CA; Antonozzi I
J Inherit Metab Dis; 2000 Sep; 23(6):563-70. PubMed ID: 11032331
[TBL] [Abstract][Full Text] [Related]
35. Long-term changes in glutamatergic synaptic transmission in phenylketonuria.
Glushakov AV; Glushakova O; Varshney M; Bajpai LK; Sumners C; Laipis PJ; Embury JE; Baker SP; Otero DH; Dennis DM; Seubert CN; Martynyuk AE
Brain; 2005 Feb; 128(Pt 2):300-7. PubMed ID: 15634735
[TBL] [Abstract][Full Text] [Related]
36. Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo.
Möller HE; Weglage J; Wiedermann D; Vermathen P; Bick U; Ullrich K
Brain Res; 1997 Dec; 778(2):329-37. PubMed ID: 9459550
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU).
Harding CO; Winn SR; Gibson KM; Arning E; Bottiglieri T; Grompe M
J Inherit Metab Dis; 2014 Sep; 37(5):735-43. PubMed ID: 24487571
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of neutral amino acid transport across the human blood-brain barrier by phenylalanine.
Shulkin BL; Betz AL; Koeppe RA; Agranoff BW
J Neurochem; 1995 Mar; 64(3):1252-7. PubMed ID: 7861158
[TBL] [Abstract][Full Text] [Related]
39. Beneficial Effects of Slow-Release Large Neutral Amino Acids after a Phenylalanine Oral Load in Patients with Phenylketonuria.
Scala I; Concolino D; Nastasi A; Esposito G; Crisci D; Sestito S; Ferraro S; Albano L; Ruoppolo M; Parenti G; Strisciuglio P
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836270
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
